Indications for Topamax
Topamax is indicated in the United States as monotherapy and adjunctive therapy for:
- partial-onset seizures in adults and children ages 2-16 years
- primary, generalized tonic-clonic seizures in adults and children ages 2-16 years
- seizures associated with Lennox-Gastaut syndrome in people 2 years of age and older
Topamax is approved by the Food and Drug Administration (FDA) as initial monotherapy for patients 10 years of age and older with partial-onset or primary generalized tonic-clonic seizures.
Topamax tablets and Topamax Sprinkle Capsules are also FDA approved for the prevention of migraine headaches in adult patients.
